Hunter C. Smith is CFO at RHYTHM PHARMACEUTICALS, INC. (RYTM). They have made 10 open-market trades across 1 company since 2022, most recently 2026-08-31.
CIK 0001636385
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RYTM | 114,024 | $9.8M |
| GWR | 11,824 | $1.3M |
| Total | $11.2M |
Shares reported on the most recent Form 4, priced at the 2026-09-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RYTM | SELL · 10b5-1 | 2026-08-31 | 2026-09-01 | $105.46 | $6.6M | -3.4% | -11.8% | — |
| RYTM | SELL | 2026-02-17 | 2026-02-19 | $101.31 | $806K | -13.0% | -17.8% | -12.0% |
| RYTM | SELL | 2026-02-10 | 2026-02-12 | $100.21 | $709K | +3.3% | -5.8% | -2.5% |
| RYTM | SELL | 2026-02-04 | 2026-02-06 | $106.03 | $703K | -0.4% | -10.2% | -7.1% |
| RYTM | SELL · 10b5-1 | 2025-08-12 | 2025-08-14 | $96.31 | $5.1M | +4.7% | -0.6% | +1.3% |
| RYTM | SELL · 10b5-1 | 2025-07-09 | 2025-07-11 | $78.93 | $4.8M | +1.3% | +8.8% | +15.6% |
| RYTM | SELL · 10b5-1 | 2025-05-30 | 2025-06-03 | $61.41 | $2.9M | -4.2% | +0.1% | +58.7% |
| RYTM | SELL · 10b5-1 | 2025-02-19 | 2025-02-19 | $57.22 | $253K | -9.4% | -10.0% | +10.5% |
| RYTM | SELL · 10b5-1 | 2025-02-12 | 2025-02-14 | $56.39 | $42K | -6.3% | -7.5% | +6.3% |
| RYTM | SELL · 10b5-1 | 2025-02-11 | 2025-02-11 | $57.51 | $149K | -3.1% | -10.9% | +4.6% |
| RYTM | SELL | 2025-02-04 | 2025-02-04 | $59.43 | $199K | -6.2% | -14.5% | +6.6% |
| RYTM | SELL | 2024-03-19 | 2024-03-19 | $39.22 | $1.2M | +9.9% | -1.9% | +6.0% |
| RYTM | SELL | 2024-02-12 | 2024-02-13 | $51.03 | $160K | -7.7% | -20.0% | -19.6% |
| RYTM | SELL | 2024-02-01 | 2024-02-05 | $45.06 | $146K | +10.0% | -10.5% | -4.4% |
| RYTM | SELL | 2023-12-05 | 2023-12-07 | $37.96 | $1.3M | +23.5% | +19.2% | +10.1% |
| RYTM | SELL | 2023-11-24 | 2023-11-28 | $35.02 | $769K | +12.4% | +45.1% | +42.2% |
| RYTM | SELL | 2023-11-14 | 2023-11-16 | $30.38 | $365K | -1.2% | +36.5% | +52.5% |
| RYTM | SELL · 10b5-1 | 2023-02-14 | 2023-02-14 | $26.87 | $19K | -8.7% | -33.2% | -37.5% |
| RYTM | SELL · 10b5-1 | 2023-02-09 | 2023-02-14 | $27.51 | $39K | -8.7% | -33.2% | -37.5% |
| RYTM | SELL · 10b5-1 | 2023-02-09 | 2023-02-13 | $27.66 | $39K | -9.8% | -32.2% | -37.1% |
| RYTM | SELL · 10b5-1 | 2022-07-01 | 2022-07-06 | $4.08 | $31K | +140.1% | +327.0% | +424.1% |
| RYTM | SELL · 10b5-1 | 2022-02-15 | 2022-02-15 | $6.10 | $5K | +13.7% | +60.6% | -51.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.